Fabrizio Pane

Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale.

Helen E White, Dong-Wook Kim, Timothy Hughes, 2013, Clinical chemistry.

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.

Simona Soverini, Giovanni Martinelli, Thomas Ernst, 2011, Blood.

Metabolic Tumor Volume Assessed by 18F-FDG PET/CT for the Prediction of Outcome in Patients with Multiple Myeloma

Michele Larobina, Marco Salvatore, Silvana Del Vecchio, 2012, The Journal of Nuclear Medicine.

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Francisco Cervantes, Simona Soverini, Giovanni Martinelli, 2013, Blood.

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.

Susan Branford, Ricardo Pasquini, Fabrizio Pane, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study

Susan Branford, Timothy P. Hughes, Fabrizio Pane, 2014, International Journal of Hematology.

Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia.

Myriam Alcalay, Giovanni Roti, Brunangelo Falini, 2006, Blood.

Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia

Paola Fazi, Marco Vignetti, Pier Giuseppe Pelicci, 2008, Haematologica.

Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia.

Giovanni Martinelli, Nicola Esposito, Giuseppe Saglio, 2014, Leukemia research.

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study.

Giovanni Martinelli, Arnon Nagler, Giovanna Rege-Cambrin, 2009, Blood.